Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 47Carcinoma, Non-Small-Cell Lung 30Pancreatic Neoplasms 24Ovarian Neoplasms 23Fallopian Tube Neoplasms 21Triple Negative Breast Neoplasms 15Breast Neoplasms, Male 14Brenner Tumor 12Melanoma 10Carcinoma, Ovarian Epithelial 10Unspecified Adult Solid Tumor, Protocol Specific 8Lung Neoplasms 8Uterine Cervical Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Adenocarcinoma of Lung 7Urinary Bladder Neoplasms 6Neoplasms 6Adenocarcinoma, Bronchiolo-Alveolar 6Neoplasm Metastasis 5Stomach Neoplasms 4Esophageal Neoplasms 4Endometrial Neoplasms 4Cholangiocarcinoma 4Pleural Effusion, Malignant 3Inflammatory Breast Neoplasms 3Gallbladder Neoplasms 3Carcinoma, Transitional Cell 3Uveal Melanoma 2Tongue Neoplasms 2Thymoma 2

Interventions

trastuzumab biosimilar HLX02 1Trastuzumab 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Bladder Urothelial Carcinoma × Taxes × Clear all
NCT00238420 2022-07-19

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 10 charts
Genitourinary

Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡